From Data Silos to GxP Compliance with AI
In this episode of the Driving the Business of Science podcast, host Keith Parent, CEO of Court Square Group, and Catherine Lunardi, CEO of GenAIz discuss how Artificial Intelligence (AI) is helping life sciences organizations strengthen compliance and regulatory accuracy across GxP operations.
GenAIz, an AI company focused on data orchestration for life sciences, recently launched AIHQ an AI-powered holistic quality management system to automate and digitize critical processes like batch record review and CAPA. Their goal is to reduce costs and risks, with potential savings up to 75%. GenAIz is also developing AI tools to improve tech transfer.
They also discuss how the Canadian government supports various AI initiatives through financial incentives to help companies adopt AI and automate processes.
Listen on your favorite podcast platforms
iHeart Radio | Apple Podcasts | Spotify | Amazon Music | Buzzsprout
Guest Profile – Catherine Lunardi, CEO, GenAIz
With over 25 years of experience deploying technologies in the life sciences industry, Mrs. Lunardi has gained an extensive understanding of data and systems in the healthcare industry.
Her experience has led her to create GenAIz in May 2016, a unique patented Artificial Intelligence Platform that can ingest, normalize, standardize and provide an overview of data from various systems in a flexible manner. GenAIz is the result of Mrs. Lunardi vision: a GxP ready data orchestration platform dedicated to the life science industry that accelerates processes execution, improves accuracy and reduce costs, thus allowing companies to bring better, safer products to the market, faster.
Before founding GenAIz, she also founded UNI3T, and led many successful projects at GSK, CGI, Héma-Québec and others.
Introduction and Overview of Court Square Group
- Keith Parent introduces himself as the CEO of Court Square Group and the host of the “Driving the Business of Science” podcast.
- Keith explains the purpose of the podcast, which is to highlight the contributions of various individuals in the drug and medical device development industries.
- Keith mentions that Catherine Lunardi, CEO of GenAIz, is a returning guest and will discuss her company’s work.
- Keith provides an overview of Court Square Group, a managed service firm that specializes in IT infrastructure for life science companies, including an Audit-Ready Compliant Cloud environment called ARCC.
Introduction of Catherine Lunardi and GenAIz
- Catherine Lunardi introduces herself as the CEO and founder of GenAIz, an AI company focused on data orchestration for life sciences.
- Catherine explains that GenAIz uses AI to ensure compliance and regulatory accuracy in GXP processes, including quality review, CAPA, and validation processes.
- Catherine emphasizes the importance of ethical and compliant AI, aiming for strong ROIs and accuracy in reports and reviews.
- Keith mentions a project with GenAIz involving the licensing of a drug product from a foreign country and the use of an AI tool called DueDilligence.AI for document analysis.
Discussion on AIHQ and AI in Life Sciences
- Keith and Catherine discuss the AIHQ concept, which stands for AI-powered holistic quality management.
- Catherine explains that AIHQ focuses on quality and regulatory compliance for the life science industry, addressing the challenges of digitization and paper-based processes.
- Catherine highlights the first two products in the AIHQ roadmap: Conformity Check and Risk Relief, which automate the digitization and review of paper batch records.
- Catherine details the benefits of these products, including cost savings, reduced risk, and improved accuracy in batch record review.
Application of AI in Different Industries
- Keith inquires about the types of companies GenAIz works with, including pharmaceutical companies, biotechs, and medical device companies.
- Catherine explains that GenAIz works with CDMOs, large pharmaceutical companies, and is developing an offer for a biotech company.
- Catherine discusses the unique challenges of biotech, where the process is more sensitive and generates stronger ROIs from AI applications.
- Keith and Catherine discuss the differences between small molecule pharmaceuticals and large molecule biologics, emphasizing the importance of AI in both areas.
Collaboration with the Canadian Government
- Keith asks Catherine about GenAIz collaboration with the Canadian government and the financial incentives provided.
- Catherine explains that the Canadian government offers financial incentives to help companies adopt AI and automate processes.
- Catherine mentions the AI for All plan by the Minister of AI, which includes additional incentives to make companies more effective and autonomous.
- Catherine outlines the next cohort’s focus on automating processes like APQR (Annual Product Quality Review), validation, and tech transfer, with a two-year program involving multiple cohorts.
Final Thoughts and Future Plans
- Keith and Catherine discuss the importance of ethical and compliant AI in critical processes, especially in the life science industry.
- Catherine emphasizes the need for AI to perform as planned and the importance of addressing the limitations of AI technology.
- Catherine highlights the opportunities for GenAIz to partner with companies in the pharmaceutical industry to automate critical processes.
- Keith encourages listeners to consider working with GenAIz, especially if they are in Canada and can benefit from the government’s financial incentives.
Episode FAQs
How does AI help solve data silos in life sciences companies?
AI platforms can ingest, normalize, and standardize data from multiple disconnected systems, giving life sciences companies a unified view of information that would otherwise remain trapped in separate databases and formats. This “data orchestration” approach reduces manual reconciliation work, speeds up processes like batch record review, and improves the accuracy of quality and regulatory reporting. For GxP-regulated organizations, breaking down data silos is often a prerequisite for reliable compliance reporting.
What is an AI-powered quality management system (QMS) in a GxP environment?
An AI-powered QMS uses artificial intelligence to automate and digitize core quality processes such as batch record review, CAPA (Corrective and Preventive Action) tracking, and validation documentation, rather than relying on manual, paper-based review. These systems are designed to maintain GxP compliance while reducing the time and labor costs associated with quality checks. Vendors in this space report cost and risk reductions of up to 75% when digitizing previously paper-based batch record processes.
Can AI be used for batch record review and CAPA management?
Yes — AI tools can automatically check batch records for conformity against predefined standards and flag deviations for human review, which significantly reduces the time quality teams spend on manual line-by-line checks. The same AI infrastructure can also support CAPA processes by helping identify root causes and track corrective actions across product lines. This automation is particularly valuable for CDMOs and pharmaceutical manufacturers managing high volumes of paper-based quality documentation.
Is AI adoption in pharma and biotech regulated or overseen by any compliance standards?
Yes — AI tools used in GxP processes must operate within existing regulatory frameworks, meaning any AI-generated output related to quality, manufacturing, or compliance still requires human oversight and validation. Life sciences companies deploying AI must ensure the technology performs consistently as intended and maintains data integrity, since AI is being layered on top of, not replacing, established GxP requirements. Ethical and compliant AI deployment is an ongoing focus for vendors serving pharma, biotech, and medical device companies.
Are there government incentives available for life sciences companies adopting AI?
In some regions, government programs offer financial incentives to help life sciences companies adopt AI and automate manual processes such as batch record review, Annual Product Quality Review (APQR), validation, and technology transfer. For example, Canada has supported such initiatives through national AI adoption plans aimed at making companies more efficient and autonomous. Companies considering AI adoption should check with local economic development or innovation agencies to see what funding or cohort-based programs may be available in their region.